NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT02588404 2024-12-10
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Withdrawn
NCT02678520 2016-07-22
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
Phase 2 Withdrawn
NCT01240928 2013-08-20
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT01240941 2013-08-20
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT01013506 2013-05-23
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn